Health care consulting firm Vynamic opens new office in London

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/ZoltanGabor)
(Image: Getty/ZoltanGabor)

Related tags: Consulting, UDG Healthcare

With offices in Philadelphia and Boston, Vynamic’s London office – co-located with STEM Healthcare – is the company’s first outside the US as it looks to support existing and new clients globally.

The health care industry management consulting firm, which was acquired by UDG Healthcare in 2018, provides strategic planning, vendor selection and management, process design, systems implementation, and organizational change services.

Jeff Dill, CEO of Vynamic, said the expansion enables the company to continue serving its customers on an international scale, while also making its services available to new clients across all sectors of health care.

“London is a world-renowned pioneer in healthcare and a global leader in research, innovation, and commercialization. It also has a large concentration of top management consulting talent. These two factors make it the perfect home for Vynamic’s international expansion,”​ Dill told us.

The company is hiring at the new London office, which is currently staffed by Gemma Pfister, who joins from UDG Healthcare’s former InterPhase Consult, and Michael Hudson, who relocated from Vynamic’s Philadelphia office.

Related topics: Markets & Regulations, Regulatory affairs

Related news

Related products

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more